Lymphedema Self-assessment Among Endometrial Cancer Survivors
Overview
Authors
Affiliations
Purpose: Lower extremity lymphedema (LEL), which causes ankle, leg, and feet swelling, poses a significant challenge for endometrial cancer survivors, impacting physical functioning and psychological well-being. Inconsistent LEL diagnostic methods result in wide-ranging LEL incidence estimates.
Methods: We calculated the cumulative incidence of LEL based on survivor-reported Gynecologic Cancer Lymphedema Questionnaire (GCLQ) responses in addition to survivor- and nurse-reported leg circumference measurements among a pilot sample of 50 endometrial cancer survivors (27 White, 23 Black) enrolled in the ongoing population-based Carolina Endometrial Cancer Study.
Results: Self-leg circumference measurements were perceived to be difficult and were completed by only 17 survivors. Diagnostic accuracy testing measures (sensitivity, specificity, positive and negative predictive value) compared the standard nurse-measured 10% difference in leg circumference measurements to GCLQ responses. At a mean of ~11 months post-diagnosis, 54% of survivors met established criteria for LEL based on 4 GCLQ cutpoint while 24% had LEL based on nurse-measurement. Percent agreement, sensitivity, and specificity approximated 60% at a threshold of 5 GCLQ symptoms. However, Cohen's kappa, a measure of reliability that corrects for agreement by chance, was highest at 4 GCLQ symptoms (κ = 0.27).
Conclusion: Our findings emphasize the need for high quality measurements of LEL that are feasible for epidemiologic study designs among endometrial cancer survivors. Future studies should use patient-reported survey measures to assess lymphedema burden and quality of life outcomes among endometrial cancer survivors.
Sentinel Lymph Node in Endometrial Hyperplasia: State of the Art and Future Perspectives.
Billone V, De Paola L, Conti E, Borsellino L, Kozinszky Z, Giampaolino P Cancers (Basel). 2025; 17(5).
PMID: 40075622 PMC: 11898874. DOI: 10.3390/cancers17050776.
Larsen G, Jensen S, Von Heymann A, Rafn B Acta Oncol. 2025; 64:326-330.
PMID: 40013604 PMC: 11884415. DOI: 10.2340/1651-226X.2025.42249.
Meyer H, Hinz A, Weisgerber C, Pilny A, Dornhofer N, Mehnert-Theuerkauf A Arch Gynecol Obstet. 2024; .
PMID: 39715839 DOI: 10.1007/s00404-024-07886-4.
Survivorship preparedness and activation among survivors of lymphoma.
Manne S, Hudson S, OMalley D, Devine K, Matasar M, Peram J J Cancer Surviv. 2024; .
PMID: 39190132 DOI: 10.1007/s11764-024-01664-6.